Year archive

Nanjing Leads Biolabs Co., Ltd. — 2026 filings

All 32 regulatory filings released by Nanjing Leads Biolabs Co., Ltd. (9887) in 2026, sourced directly from the official regulator.

32 Filings

2026 Period

2026 filings (32)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET ACQUISITION OF H SHARES BY THE TRUSTEE IN THE AMOUNT OF UP TO US$50 MILLION UNDER THE H SHARE AWARD SCHEME Transaction in Own Shares	2026-05-20	English
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR ADVANCED EXTRAPULMONARY NEUROENDOCRINE CARCINOMA (EP-NEC) APPROVED BY CDE Regulatory Filings	2026-05-19	English
ARTICLES OF ASSOCIATION Governance Information	2026-05-15	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION Declaration of Voting Results & Voting Rights Announcements	2026-05-15	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Governance Information	2026-05-15	English
INSIDE INFORMATION LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY Share Issue/Capital Change	2026-05-14	English
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION AND PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY Regulatory Filings	2026-05-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 Regulatory Filings	2026-05-06	English
VOLUNTARY ANNOUNCEMENT - LBL-047 PRIORITIZED FOR CLINICAL DEVELOPMENT IN SJOGREN'S DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS, AND DERMATOMYOSITIS Regulatory Filings	2026-05-06	English
PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026 Proxy Solicitation & Information Statement	2026-04-24	English
(1) 2025 WORK REPORT OF THE BOARD OF DIRECTORS; (2) 2025 FINAL FINANCIAL REPORT; (3) 2025 ANNUAL REPORT; (4) 2025 PROFIT DISTRIBUTION PLAN; (5) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; (6) RE-A Proxy Solicitation & Information Statement	2026-04-24	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2026-04-24	English
2025 ANNUAL REPORT Annual Report FY 2025	2026-04-24	English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2026-04-24	English
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION Regulatory Filings	2026-04-24	English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN PHASE II TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR FIRST-LINE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA Regulatory Filings	2026-04-21	English
VOLUNTARY ANNOUNCEMENT - PHASE II STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR BILIARY TRACT CANCER SUCCESSFULLY ENTERS EXPANSION PHASE Regulatory Filings	2026-04-08	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026 Regulatory Filings	2026-04-01	English
VOLUNTARY ANNOUNCEMENT - RESEARCH ABSTRACTS ACCEPTED FOR PRESENTATION AT THE 2026 AACR ANNUAL MEETING Regulatory Filings	2026-03-31	English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS Governance Information	2026-03-27	English
(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR; (2) PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND (3) CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE Board/Management Information	2026-03-27	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 Earnings Release FY 2025	2026-03-27	English
DATE OF BOARD MEETING Report Publication Announcement	2026-03-17	English
VOLUNTARY ANNOUNCEMENT - INCLUSION AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX AND INCLUSION IN THE STOCK LIST OF STOCK CONNECT SOUTHBOUND TRADING LINK Regulatory Filings	2026-03-06	English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT ENROLLED IN PHASE II TRIAL OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) FOR FIRST-LINE ESOPHAGEAL SQUAMOUS CELL CARCINOMA Regulatory Filings	2026-03-06	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026 Regulatory Filings	2026-03-03	English
VOLUNTARY ANNOUNCEMENT - LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) DOSED FIRST PATIENT IN PHASE IB/II TRIAL FOR RECURRENT OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER Regulatory Filings	2026-02-10	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026 Share Issue/Capital Change	2026-02-03	English
VOLUNTARY ANNOUNCEMENT - LBL-034 (GPRC5D/CD3 BISPECIFIC T-CELL ENGAGER, TCE) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA Regulatory Filings	2026-01-28	English
VOLUNTARY ANNOUNCEMENT ORPHAN DRUG DESIGNATION (ODD) OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) BY THE EUROPEAN COMMISSION FOR THE TREATMENT OF EXTRAPULMONARY NEUROENDOCRINE CARCI Regulatory Filings	2026-01-22	English
VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA Regulatory Filings	2026-01-14	English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025 Regulatory Filings	2026-01-05	English